erlotinib hydrochloride has been researched along with cediranib in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (cediranib) | Trials (cediranib) | Recent Studies (post-2010) (cediranib) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 279 | 102 | 204 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | cediranib (IC50) |
|---|---|---|---|
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | 0.005 | |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | 0.026 | |
| Platelet-derived growth factor receptor alpha | Homo sapiens (human) | 0.036 | |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | 0.005 | |
| Vascular endothelial growth factor receptor 3 | Homo sapiens (human) | 0.003 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.0016 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Klempner, SJ; Mills, GB; Myers, AP; Westin, SN | 1 |
1 review(s) available for erlotinib hydrochloride and cediranib
| Article | Year |
|---|---|
Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
Topics: Antineoplastic Agents; Benzodioxoles; Carcinoma, Ovarian Epithelial; Erlotinib Hydrochloride; Female; Humans; Indazoles; Indoles; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sulfonamides | 2013 |